LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Investigated for use/treatment in thrombosis and venous thromboembolism.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.